Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmo NVXSWX:COPN +1.31%80 Equity-to-Asset is 0.82 as of Jun. 2026, which is 12% above its 10-year median of 0.73. GuruFocus rates XSWX:COPN with a GF Score™ of 80/100 and a GF Value™ of CHF40.67 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Cosmo NV ranks better than 82.92% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cosmo NV's Total Stockholders Equity for the quarter that ended in Jun. 2026 was CHF520.52 Mil. Cosmo NV's Total Assets for the quarter that ended in Jun. 2026 was CHF638.60 Mil.
Therefore, Cosmo NV's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.82.
The historical rank and industry rank for Cosmo NV's Equity-to-Asset or its related term are showing as below:
XSWX:COPN'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.59 Med: 0.73 Max: 0.95
Current: 0.82
During the past 13 years, the highest Equity to Asset Ratio of Cosmo NV was 0.95. The lowest was 0.59. And the median was 0.73.
XSWX:COPN's Equity-to-Asset is ranked better than 82.92% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs XSWX:COPN: 0.82
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cosmo NV Equity-to-Asset Related Terms
Cosmo NV Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Cosmo NV's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:COPN vs LLY, JNJ, ABBV: Equity-to-Asset Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cosmo NV's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV (XSWX:COPN) has a Equity-to-Asset of 0.82 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cosmo NV and its competitors. This is 12% above median its historical median of 0.73. Over the past decade, Cosmo NV's Equity-to-Asset has ranged from 0.59 to 0.95. According to the industry distribution chart, Cosmo NV ranks #172 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 17.1%.
Is Cosmo NV's Equity-to-Asset too high?
Cosmo NV's current Equity-to-Asset of 0.82 is 12% above median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 0.95. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Cosmo NV's value of 0.82 is 34.4% above this industry median. Based on the distribution chart, Cosmo NV ranks #172 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmo NV has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Equity-to-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #172 out of 1007 companies for Equity-to-Asset. This places Cosmo NV in the top 17% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.61. Cosmo NV's value of 0.82 is 34.4% above this benchmark. Historically, Cosmo NV's own Equity-to-Asset has ranged from 0.59 to 0.95 over the past decade. While the company's 10-year median is 0.73 vs. the industry median of 0.61, Cosmo NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current Equity-to-Asset of 0.82 is 34.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current Equity-to-Asset is 0.82, which is 12% above median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (XSWX:COPN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF40.67, compared to a current price of CHF61.70 — trading 51.7% above its estimated fair value. The current Equity-to-Asset is 0.82, which is 12% above median its 10-year median of 0.73 and 34.4% above the Drug Manufacturers industry median of 0.61. Cosmo NV's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cosmo NV (XSWX:COPN), the current Equity-to-Asset is 0.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (XSWX:COPN) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of CHF61.70 is trading 51.7% above its estimated GF Value™ of CHF40.67.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for XSWX:COPN:
Equity-to-Asset: 0.82 (12% above median its 10-year median of 0.73)
GF Value™: CHF40.67 vs. price of CHF61.70 (51.7% above fair value)
Industry Position: 34.4% above the Drug Manufacturers median (#172 of 1007)
No single metric tells the full story. See the XSWX:COPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
80GF Score
Get the complete analysis for XSWX:COPN
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:COPN has been successfully added to your 
